8-K - Connect Biopharma Holdings Limited | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Connect Biopharma entered into a securities purchase agreement for a $20.2 million private placement of 6.130 million ordinary shares and announced positive Phase 1 IV rademikibart data and Phase 3 AD results from Simcere.

Key Takeaways

1Entered securities purchase agreement on March 29, 2026 for 6,130,000 ordinary shares at $3.25 per share, expecting $20.2 million gross proceeds.

2Private placement expected to close March 31, 2026, led by Panacea Venture with Leerink Partners LLC and Cantor Fitzgerald & Co. as placement agents.

3Net proceeds to fund R&D of clinical-stage product candidates, working capital, extending cash runway into second half of 2027.

4Phase 1 study showed IV rademikibart 300 mg produced rapid FEV1 improvements of 200-400 mL in asthma/COPD patients, maintained through Day 29.

5Simcere's Phase 3 52-week AD study showed rademikibart achieved 96.6% EASI-75, 87.1% IGA 0/1, and 85.3% EASI-90 at Week 52.

6Issued press releases on March 30, 2026 announcing clinical results and private placement (Exhibits 99.1, 99.2, 99.3).

Current Report Details

Event Type

Material Agreement+4 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On March 29, 2026, Connect Biopharma Holdings Limited (the “Company”) entered into a securities purchase agreement (

Material Agreement

$3.25$20.2M

Source Document

3.02

Unregistered Sales of Equity Securities. The disclosures set forth in Item 1.01 above are incorporated by reference into this Item 3.02. Item 7.01 Regulation FD

Securities Issuance

7.01

, including Exhibits 99.1, 99.2 and 99.3, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan

Regulation Fd

8.01

Other Events. On March 30, 2026, the Company issued a press release announcing topline preliminary results for its Phase 1 clinical pharmacology study evaluatin

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No.: 10.1 | Description: Securities Purchase Agreement, dated March 29, 2026, by and between Connect Bio

Exhibits Only

Source Document

Transaction Details

Material Agreement

Agreement: Securities Purchase Agreement
Parties: Connect Biopharma Holdings Limited, Purchasers

•Private placement of 6,130,000 ordinary shares at $3.25 per share
•Aggregate gross proceeds approximately $20.2 million
•Closing expected March 31, 2026 subject to customary conditions
•Use of proceeds for R&D, working capital and general corporate purposes
•File resale registration statement with SEC within 45 days post-closing
•Conducted per Section 4(a)(2) and Rule 506 of Regulation D

Exhibits (5)

10.1

EX-10.1

8-K

99.1

EX-99.1

99.2

EX-99.2

99.3

EX-99.3